期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

酪氨酸激酶抑制剂耐药机制及其治疗策略 被引量：4

Resistant Mechanism and Treatment Strategy of Tyrosine Kinase Inhibitors
下载PDF
导出
摘要 人类表皮生长因子受体（epidermal growth factor receptor,EGFR）是原癌基因C-erbB1的表达产物,属于酪氨酸激酶生长因子受体家族成员之一,在人类多种实体肿瘤中过度表达,与肿瘤细胞的增殖、侵袭、转移及血管生长等有关。
作者 乔建兵 陈文萍
机构地区 南京市胸科医院呼吸内科
出处 《中国肺癌杂志》 CAS 2011年第10期806-810,共5页 Chinese Journal of Lung Cancer
关键词 酪氨酸激酶抑制剂 人类表皮生长因子受体 耐药机制 RECEPTOR 治疗 表达产物 原癌基因 家族成员
分类号 R734.2 [医药卫生—肿瘤]
  • 相关文献

参考文献39

  • 1O-charoenrat P, Rhys-Evans PH, Archer DJ, et al. C-erbB receptor in squamous cell carcinomas of the head and neck: clinical significance and correlation with matrix metalloproteinases and vascular endothelial growth factors. Oral Oncol, 2002, 38( 1): 73-80.
  • 2Koutsopoulos AV, Mavroudis D, Dambaki KI, et al. Simultaneous expression of c-erbB-1, c-erbB-2, c-erbB-3 and c-erbB-4 receptors in non-small-cell lung carcinomas: correlation with clinical outcome. Lung Cancer, 2007, 57(2): 193-200.
  • 3Tiseo M, Rossi G, Capelletti M, et al. Predictors of gefitinib outcomes in advanced non-small cell lung cancer (NSCLC): study of a comprehensive panel of molecular markers. Lung Cancer, 2010, 67(3): 355-360.
  • 4Kim DW, Lee SH, Lee JS, et al. A multicenter phase II study to evaluate the efficacy and safety ofgefitinib as first line treatment for Korean patients with advanced pulmonary adenocarcinoma harboring EGFR mutations. Lung Cancer, 2011, 71(1): 65-69.
  • 5Shoji F, Yano T, Yoshino I, et al. The characteristics and failure pattern of gefitinib responders with postoperative recurrence of pulmonary adenocarcinoma. EurJ Surg Oncol, 2008, 34(1): 89-93.
  • 6Sugio K, Uramoto H, Onitsuka T, et al. Prospective phase II study ofgefitinib in non-small cell lung cancer with epidermal growth factor receptor gene mutations. Lung Cancer, 2009, 64(3): 314-318.
  • 7Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N EnglJ Med, 2009, 361 (10): 947-957.
  • 8Chen HJ, Mok TS, Chen ZH, et al. Clinicopathologic and molecular features of epidermal growth factor receptor T790M mutation and c-MET amplification in tyrosine kinase inhibitor-resistant Chinese non-small cell lung cancer. Pathol Oncol Res, 2009, 15(4): 651-658.
  • 9Uramoto H, Shimokawa H, Hanagiri T, et al. Expression of selected gene for acquired resistance to EGFR-TKI in lung adenocarinma. Lung Cancer 2011, 73(3): 361-365.
  • 10Taus A, Vollmer I, Arriola E. Activating and resistance mutations of the epidermal growth factor receptor (EGFR) gene and non-small celI lung cancer: a clinical reality. Arch Bronconeumol, 2011, 47(2): 103-105.

二级参考文献32

  • 1高霞,刁路明,李恒,夏东,凌长明,刘铭球.非小细胞肺癌中肝细胞生长因子受体蛋白表达及其与肿瘤细胞增殖、血管生成的关系[J].武汉大学学报（医学版）,2005,26(3):273-275. 被引量：5
  • 2高尚志.我国心胸外科实验研究目前的热点和问题[J].中华实验外科杂志,2006,23(9):1031-1032. 被引量：3
  • 3Suzuki M,Shigematsu H,Hiroshima K,et al.Epidermal growth factor receptor expression status in lung cancer correlates with its mutation.Hum Pathol,2005,36:1 127-1 134.
  • 4Janmaat M,Rodriguez J,Ruiz M,et al.Enhanced cytotoxicity induced by gefitinib and specific inhibitors of the Ras or phosphatidylinositol-3 kinase pathways in non-small cell lung cancer cells.Int J Cancer,2006,118:209-214.
  • 5Maulik G, Shrikhande A, Kijima T, et al. Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and poten tial for therapeutic inhibition [J]. Cytokine Growth Factor Rev, 2002,13(1) :41-59.
  • 6RosarioM, BirchmeierW. How tO make tubes: signaling by the Met receptor tyrosine kinase [J]. Trends Cell Biol, 2003,13: 328-35.
  • 7Recio JA, Merlino G. Hepatocyte growth factor/scatter factor activates proliferation in melanoma cells through p38 MAPK/ ATF and cyclinD1 [J]. Oncogene, 2002,21(7):1000-1008.
  • 8Paumelle R, Tulasne D, Kherrouche Z, et al. Hepatocyte growth Factor/scatter factor activates the ETS1 transcription factor by a RAS-RAF MEK-ERK signaling pathway [J]. Oncogene, 2002,21 (15) : 2309-2319.
  • 9Ichimura E, Maeshima A, Nakajima T, et al. Expression of c- met/HGF receptor in human non-small cell lung carcinomas in vitro and in vivo and its prognostic significance [J]. Jpn J Cancer Res, 1996,87(10):1063-1069.
  • 10Siegfried JM, Weissfeld LA, Singh-Kaw P, et al. Association of immunoreaetive hepatocyte growth factor with poor survival in rer, cctable non-small cell lung cancer [J]. Cancer Res, 1997, 57(3) :133-439.

共引文献15

同被引文献55

  • 1曾益新.主编.肿瘤学.3版[M].北京:人民卫生出版社,2012:623-636.
  • 2胡联民,蔡凯.鼻咽癌治疗的研究进展[J].医学信息,2012.25(6):379-380.
  • 3张为远,吴玉梅,主编.官颈病变与官颈癌[M].北京:人民卫生出版社,2012:255-256.
  • 4Hackel PO, Zwick E, Prenzel N, et al. Epidermal growth factor reeeptors:eritieal mediators of multiple receptor pathways[J]. Curr Opin Cell Biol, 1999,11 (2) : 184-189.
  • 5Dewdney A, Cunningham D, Tabernero J, et al. Multicenter randomized phase Ⅱ clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C)[J]. J Clin Oncol, 2012, 30(14) : 1620-1627.
  • 6Sun PL, Li B, Ye QF. Effect of neoaajuvant cetuximab, capecitabine,and radiotherapy for locally advanced rectal cancer: results of a phase Ⅱ study[J].IntJ Coloreetal Dis, 2012,27(10): 1325-1332.
  • 7Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for loco regionally advanced head and neck cancer: 5- year survival data from a phase 3 randomized trial, and relation between cetuximab-induced rash and survival [ J]. I.aneet Oncol, 2010,11(1) :21-28.
  • 8Okano S,Yoshino T,Fujii M, et al. Phase Ⅱ study of cetuximab plus concomitant boost radiotherapy in Japanese patients with locally advanced squamous cell carcinoma of the head and neck[J]. Jpn J Clin Oncol,2013,43(5) :476-482.
  • 9Chen Y, Wu X, Bu S, et al. Promising outcomes of definitive chemoradiation and cetuximab for patients with esophageal squamouscell carcinoma[J]. Cancer Sci, 2012, 103 (11): 1979- 1984.
  • 10Crosby T, Hurt CN, Falk S, et al. Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1) : a multicentre,phase 2/3 randomized trial[J]. Lancet Oncol, 2013, 14(7) : 627-637.

引证文献4

二级引证文献2

中国肺癌杂志
2011年 第10期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部